The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

The findings suggest that lipid composition can direct mRNA-based drugs to target organs, such as the intestines, without passing through the liver.

Mark Genovese: Crohn’s disease is a chronic, inflammatory bowel disease associated with progressive bowel damage, disability, ...

A real-world study in adolescent and young adult patients with inflammatory bowel disease (IBD) found no significant ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

Takeda is serving as the Industry Lead in the newly launched INTERCEPT project to identify predictive biomarkers for Crohn's ...

The Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults.

Turmeric's active compound, curcumin, is a potent anti-inflammatory and antioxidant that can help with conditions like ...

The FDA has approved Omvoh (mirikizumab-mrkz) for treating moderately to severely active Crohn’s disease in adults. Clinical ...

Children who were diagnosed with inflammatory bowel disease (IBD) showed a decline in height, weight, and body mass index ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to ...

for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two types of inflammatory ...